Sanofi sahifasining manbasini koʻrish

{{Shirkat bilgiqutisi|nomi=Sanofi|name=Sanofi-aventis|tasvir=Sanofi-2022.svg|turi=Xalqaro farmaseftika kompaniyasi|asos solingan=2004|joylashuvi=[[Fransiya]] [[Parij]]|asoschisi=Serj Vaynberg <small>([[sobiq direktor]])</small><br />Pol Xadson ([[CEO]])</small><ref name="reuters" />|birja_listingi=Euronext|daromad=39,175 mlrd yevro <small>(2021)</small><ref name="reuters" />|operatsion_foyda=8,126 mlrd yevro <small>(2021)</small><ref name="reuters" />|toza_foyda=6,223 mlrd yevro <small>(2021)</small><ref name="reuters" />|boyligi=120,24 mlrd yevro <small>(2021)</small><ref name="reuters" />|byudjet=68,681 mlrd yevro <small>(2021)</small><ref name="reuters" />|kapitallashtirish=118,8 mlrd yevro <small>(16.03.2022)</small><ref name="reuters">{{veb manbasi|title=SASY.PA - Sanofi SA Profile|url=https://www.reuters.com/companies/SASY.PA|publisher=[[Reuters]]|accessdate=16-mart 2022-yil|lang=inglizcha|archive-date=16-mart 2022-yil|archive-url=https://web.archive.org/web/20220316193734/https://www.reuters.com/companies/SASY.PA|deadlink=no}}</ref>|ishchilar_soni=99412<ref name="forbes">{{veb manbasi|title=Sanofi (SNY)|url=https://www.forbes.com/companies/sanofi/?sh=542932841fde|publisher=[[Forbes (журнал)|Forbes]]|accessdate=16-mart 2022-yil|lang=inglizcha|archive-date=16-mart 2022-yil|archive-url=https://web.archive.org/web/20220316193737/https://www.forbes.com/companies/sanofi/?sh=542932841fde|deadlink=no}}</ref>|aʼzolari=Sanofi Pasteur, Genzyme, Chattem, Merrial|sayt=[http://sanofi.com www.sanofi.com]{{ref-en}}{{ref-fr}}|image=Sanofi Frankfurt IPH.jpg}}
'''Sanofi''' (2011-yil yozigacha Sanofi-Aventis) — xalqaro fransuz farmatseftika kompaniyasi hisoblanadi. Bu dunyodagi yetakchi farmatsevtika korporatsiyalaridan biri<ref>IMS Health 2008</ref><ref>{{Yangiliklar manbasi |last=Keller |first=Greg |date=10-sentabr 2008-yil |title=Sanofi names Viehbacher as new CEO |work=[[Associated Press]] |publisher=[[USA Today]] |url=https://www.usatoday.com/money/economy/2008-09-10-4035378426_x.htm |access-date=19-aprel 2009-yil |archive-url=https://web.archive.org/web/20090402222656/http://www.usatoday.com/money/economy/2008-09-10-4035378426_x.htm |archive-date=2-aprel 2009-yil}}</ref> boʻlib, Sanofi kompaniyasi 100 dan ortiq mamlakatlarda oʻz ih faoliyatini olib boradi. Kompaniyaning bosh qarorgohi [[Parij|Parijda]] joylashgan. [[Forbes]] Global 2021-yilda dunyodagi eng yirik kompaniyalar roʻyxatida Sanofi 72-oʻrinni egalladi (daromad boʻyicha 237-oʻrin, sof daromad boʻyicha 32-oʻrin, aktivlar boʻyicha 274-oʻrin va bozor kapitallashuvi boʻyicha 101-oʻrin).

== Tarixi ==
Sanofi tarixi 1973-yilda Elf Aquitaine davlat neft kompaniyasidan ish faoliyatini boshlangan, snu vaqtlarda farmatseftika, kosmetika va uy hayvonlari uchun oziq-ovqat boʻlimi tashkil etildi. Dastlab, bu boʻlinma sotib olingan kompaniyalar guruhidan iborat edi, ammo 1979-yilga kelib, boʻlinma boshligʻi Rene Sautier boshchiligida markazlashtirilgan farmatsevtika kompaniyasi tuzildi. 1980-yillarning birinchi yarmida Sanofi [[Amerika Qoʻshma Shtatlari|AQSh]] va [[Yaponiya]] bozorlariga chiqdi. 1983-yilda kompaniya [[Fransiya|Fransiyaning]] biotexnologiya sohasidagi eng yirik tadqiqot markazini sotib oldi<ref name="advameg">{{Veb manbasi|sarlavha=History of SANOFI GROUP|url=http://www.referenceforbusiness.com/history2/37/SANOFI-GROUP.html|nashriyot=Advameg, Inc.|qaralgan sana=20-fevral 2017-yil|til=inglizcha|arxivsana=21-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170221105736/http://www.referenceforbusiness.com/history2/37/SANOFI-GROUP.html}}</ref>. 1999-yilda oʻsha paytda Fransiyaning ikkinchi yirik farmatseftika kompaniyasi boʻlgan Sanofi uchinchi [[L'Oréal]] tomonidan boshqariladigan Synthélabo bilan birlashdi. Birlashgan kompaniya Sanofi-Synthélabo nomini oldi, L'Oreal va [[TotalEnergies|Total]] asosiy aktsiyadorlari; Birlashuvdan soʻng, kosmetika va veterinariya mahsulotlari boʻlinmalari sotildi<ref>{{Veb manbasi|sarlavha=Annual Report 2002 on SEC Filing Form 20-F|url=https://www.sec.gov/Archives/edgar/data/1121404/000095010903003612/d20f.htm#tx363_10|sana=2002|nashriyot=Sanofi-Synthélabo|kirish sanasi=20-fevral 2017-yil|til=inglizcha|arxivsana=26-avgust 2016-yil|arxivurl=https://web.archive.org/web/20160826050347/https://www.sec.gov/Archives/edgar/data/1121404/000095010903003612/d20f.htm#tx363_10}}</ref>.

Aventis 1999-yilda Rhône-Poulenc SA Hoechst Marion Roussel bilan birlashganda tashkil topgan. Birlashgan kompaniya [[Fransiya|Fransiyaning]] [[Strasburg]] yaqinidagi Shiltighaym shahrida joylashgan edi. Aventis CropScience nomi bilan tanilgan Rhône-Poulencning qishloq xoʻjaligi boʻlimi Hoechst bilan birlashgandan soʻng 2002-yilda [[Bayer|Bayerga]] sotilgan. 1998-yilda Rhone-Poulencning kimyoviy boʻlimi mustaqil Rhodia kompaniyasiga aylantirildi. 2004-yil 20-avgustda Sanofi-Synthelabo va Aventis birlashdi. Oʻsha vaqtdan beri Sanofi-Synthelabo Aventis ulush kapitalining 95,47% ga egalik qilar edi<ref>{{Veb manbasi|url=http://www.apteka.ua/article/81227|sarlavha=Компания «sanofi-aventis» сменила название|qaralgan sana=28-noyabr 2014-yil|arxivsana=3-aprel 2015-yil|arxivurl=https://web.archive.org/web/20150403082257/http://www.apteka.ua/article/81227}}</ref>. Avvalroq 2004-yilda Sanofi-Synthelabo Aventis uchun 47,8 milliard yevro taklif qilgan, biroq bu taklif rad etilgan. Fransiya hukumatining aralashuvi ham faol rol oʻynadi. Novartis ham taklif bilan chiqish niyatida ekani xabar qilinganidan keyin Fransiya hukumati Sanofi-Synthelabo kompaniyasiga bosim oʻtkazib, Aventis narxini koʻtardi.

2018-yil aprel oyidan iyun oyining oxirigacha Sanofi Zentivaning [[Chexiya]] generiklar boʻlinmasini Advent<ref>{{Veb manbasi|url=http://www.remedium.ru/news/detail.php?ID=73973|sarlavha=Advent покупает дженериковое подразделение Sanofi|qaralgan sana=1-oktabr 2018-yil|arxivsana=2-oktabr 2018-yil|arxivurl=https://web.archive.org/web/20181002020039/http://www.remedium.ru/news/detail.php?ID=73973}}</ref> ga sotish boʻyicha muzokaralar olib bordi. 2018-yil 30-sentyabrda oldi-sotdi shartnomasi kuchga kirdi. Bitim 1,9 milliard yevroni tashkil etdi. Sanofi matbuot xizmati Zentiva sotilishi kompaniya tuzilmasini tartibga solish strategiyasining bir qismi ekanligini aytdi<ref name="zentiva">{{Veb manbasi|url=http://www.remedium.ru/news/detail.php?ID=75145|sarlavha=Sanofi продала дженериковое подразделение за 1,9 млрд евро|qaralgan sana=1-oktabr 2018-yil|arxivsana=2-oktabr 2018-yil|arxivurl=https://web.archive.org/web/20181002020029/http://www.remedium.ru/news/detail.php?ID=75145}}</ref>.

2020-yil may oyida Regeneron bevosita Sanofi kompaniyasiga tegishli taxminan 5 milliard dollarlik aktsiyalarni qaytarib sotib olish niyatini eʼlon qildi.

Kompaniya 2020-yil iyul oyida Buyuk Britaniya hukumati uchun 60 million dozali [[COVID-19 koronavirus infeksiyasi|koronavirus]] vaksinasini ishlab chiqarishga kelishib oldi. Sanofi, shuningdek, 100 million doza uchun AQSh bilan 2,1 milliard dollarlik shartnoma boʻyicha muzokaralar olib bordi<ref>{{Veb manbasi|url=https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html|sarlavha=U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine|nashriyot=CNBC|qaralgan sana=18-iyun 2021-yil|arxivsana=7-fevral 2021-yil|arxivurl=https://web.archive.org/web/20210207172303/https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html}}</ref>.

Kompaniya sotib olish yoʻli bilan kengaytirildi, ulardan eng kattasi<ref name="questex">{{Veb manbasi|sarlavha=Sanofi-Aventis: A timeline of biopharma deals|url=http://www.fiercebiotech.com/special-report/sanofi-aventis-a-timeline-of-biopharma-deals|nashriyot=Questex LLC|qaralgan sana=24-fevral 2017-yil|til=inglizcha|arxivsana=24-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170224222307/http://www.fiercebiotech.com/special-report/sanofi-aventis-a-timeline-of-biopharma-deals}}</ref> quyidagilar sanaladi:

* Zentiva - 2008-yilda 1,8 milliard yevroga sotib olingan; Chexiya generik ishlab chiqaruvchisi<ref>{{Veb manbasi|sarlavha=Sanofi-Aventis Acquires Zentiva For $2.6B|url=https://www.pharmaceuticalonline.com/doc/sanofi-aventis-acquires-zentiva-2-6-billion-0001|sana=2008-09-24|nashriyot=VertMarkets, Inc.|qaralgan sana=24-fevral 2017-yil|til=inglizcha|arxivsana=24-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170224215436/https://www.pharmaceuticalonline.com/doc/sanofi-aventis-acquires-zentiva-2-6-billion-0001}}</ref>. 2018-yil sentyabr oyida Advent International<ref name="zentiva">{{Veb manbasi|url=http://www.remedium.ru/news/detail.php?ID=75145|sarlavha=Sanofi продала дженериковое подразделение за 1,9 млрд евро|qaralgan sana=1-oktabr 2018-yil|arxivsana=2-oktabr 2018-yil|arxivurl=https://web.archive.org/web/20181002020029/http://www.remedium.ru/news/detail.php?ID=75145}}</ref> ga sotilgan;
* Shantha Biotechnics - 2009-yilda 550 million yevroga sotib olingan; hind vaksina ishlab chiqaruvchisi<ref>{{Veb manbasi|sarlavha=Sanofi snaps up India's Shantha for $784M|url=http://www.fiercebiotech.com/biotech/sanofi-snaps-up-india-s-shantha-for-784m|sana=2009-07-27|nashriyot=Questex LLC.|qaralgan sana=24-fevral 2017-yil|til=inglizcha|arxivsana=24-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170224221855/http://www.fiercebiotech.com/biotech/sanofi-snaps-up-india-s-shantha-for-784m}}</ref>;
* Chattem - 2009-yilda 1,9 milliard dollarga sotilgan; Amerikalik retseptsiz dori-darmonlar va kosmetika ishlab chiqaruvchisi<ref>{{Veb manbasi|sarlavha=Drug Maker Sanofi-Aventis Buys Chattem for $1.9 Billion|url=https://www.nytimes.com/2009/12/22/business/global/22drug.html|sana=2009-12-21|nashriyot=[[The New York Times]]|qaralgan sana=24-fevral 2017-yil|til=inglizcha|arxivsana=24-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170224215659/http://www.nytimes.com/2009/12/22/business/global/22drug.html}}</ref>;
* Medley Pharmaceuticals Ltd. - 2010-yilda 500 million yevroga sotilgan; Braziliya farmatseftika kompaniyasi<ref>{{Veb manbasi|muallif=Leigh Kamping-Carder|sarlavha=https://www.law360.com/articles/169962/brazil-clears-sanofi-s-635m-medley-pharma-buy|url=Brazil Clears Sanofi's $635M Medley Pharma Buy|sana=20-may 2010-yil|nashriyot=Portfolio Media, Inc.|qaralgan sana=24-fevral 2017-yil|til=inglizcha}}</ref> ;
* Genzyume - 2011-yilda 20,1 mlrd. Amerika biotexnologiya kompaniyasi<ref>{{Veb manbasi|muallif=Chris V. Nicholson|sarlavha=Sanofi Agrees to Buy Genzyme for $20.1 Billion|url=https://dealbook.nytimes.com/2011/02/16/sanofi-agrees-to-buy-genzyme-for-at-least-20-1-billion/?_r=0|sana=2011-02-16|nashriyot=[[The New York Times]]|qaralgan sana=24-fevral 2017-yil|til=inglizcha}}</ref>;
* Globalpharma - 2014-yilda sotib olingan aksiyalarning 66%; [[Dubay|Dubayda]] joylashgan generiklar ishlab chiqaruvchisiga tegishli<ref>{{Veb manbasi|muallif=Eric Palmer|sarlavha=Sanofi buys Dubai's Globalpharma to produce generics in the Middle East|url=http://www.fiercepharma.com/supply-chain/sanofi-buys-dubai-s-globalpharma-to-produce-generics-middle-east|sana=2014-06-26|nashriyot=Questex LLC.|qaralgan sana=24-fevral 2017-yil|til=inglizcha|arxivsana=25-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170225133640/http://www.fiercepharma.com/supply-chain/sanofi-buys-dubai-s-globalpharma-to-produce-generics-middle-east}}</ref>.
* Bioverativ — Sanofi 2018-yilda gemofiliya ishlab chiqaruvchisini 11,6 milliard dollarga sotib oladi<ref>{{Veb manbasi|url=http://www.remedium.ru/news/detail.php?ID=73263|sarlavha=Sanofi покупает разработчика орфанных препаратов Bioverativ за 11,6 млрд долларов {{!}} новостной портал<!-- Заголовок добавлен ботом -->|qaralgan sana=23-yanvar 2018-yil|arxivsana=24-yanvar 2018-yil|arxivurl=https://web.archive.org/web/20180124070758/http://www.remedium.ru/news/detail.php?ID=73263}}</ref>.
* Principia Biopharma - 2020-yil avgust oyida Sanofi kompaniyani 3,7 milliard AQSh dollariga sotib olayotganini eʼlon qildi va uning BTK inhibitor dasturini sotib oldi<ref>{{Veb manbasi|url=https://www.biospace.com/article/sanofi-snaps-up-principa-biopharma-and-its-btk-program-for-100-per-share/|sarlavha=Sanofi Acquires Principia Biopharma in $3.6 Billion Deal|ish=BioSpace|qaralgan sana=11-dekabr 2020-yil|arxivsana=21-yanvar 2021-yil|arxivurl=https://web.archive.org/web/20210121070406/https://www.biospace.com/article/sanofi-snaps-up-principa-biopharma-and-its-btk-program-for-100-per-share/}}</ref>.
* Tidal Therapeutics - 2021-yil aprel oyida Sanofi kompaniyani 470 million dollarga sotib olganini eʼlon qildi<ref>{{Veb manbasi|url=https://www.biospace.com/article/sanofi-snatches-up-tidal-therapeutics-in-470-deal/?s=79|sarlavha=Sanofi Snatches Up Tidal Therapeutics in $470 Million Deal {{!}} BioSpace<!-- Заголовок добавлен ботом -->|qaralgan sana=18-iyun 2021-yil|arxivsana=13-aprel 2021-yil|arxivurl=https://web.archive.org/web/20210413192032/https://www.biospace.com/article/sanofi-snatches-up-tidal-therapeutics-in-470-deal/?s=79}}</ref>.

== Egalari va boshqaruvi ==
2021-yil oxirigacha kompaniya aktsiyadorlari<ref name="ar2021">{{Veb manbasi|sarlavha=Annual Report 2021|url=https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8|sana=2022-02-23|nashriyot=Sanofi Group|qaralgan sana=16-mart 2022-yil|til=inglizcha|arxivsana=28-fevral 2022-yil|arxivurl=https://web.archive.org/web/20220228180730/https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8}}</ref>:

* [[L'Oréal|L'Oreal]] - 9,36%,
* Black Rock - 7,04%
* kompaniya xodimlari - 1,85%,
* gʻaznachilik aksiyalari - 1,19%.

Fransiya farmaseftika ishlab chiqaruvchisi oʻzining yirik raqobatchisi Aventisni sotib olishdan oldin, [[L'Oréal|L'Oreal]] va [[TotalEnergies|Total]] Sanofi-Synthelabo<ref>[http://rccnews.ru/Rus/Chemicals/?ID=49961 Доля L’Oreal и Total в Sanofi-Aventis ]</ref> ning eng yirik aktsiyadorlari edi.

* Serj ''Vaynberg'' (1951-yil 10-fevralda tugʻilgan) 2015-yil 2-apreldan beri boshqaruv kengashining mustaqil raisi; 2009-yildan beri kompaniyada; shuningdek, Weinberg Capital Partners investitsiya kompaniyasi asoschisi va raisi.
* Pol Hudson (''Paul Hudson'', 1968-yil 14-oktabrda tugʻilgan) — 2019-yil 1-sentabrdan beri bosh ijrochi direktor; Bungacha u Novartisda uch yil shu lavozimda ishlagan<ref name="ar2021">{{Veb manbasi|sarlavha=Annual Report 2021|url=https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8|sana=2022-02-23|nashriyot=Sanofi Group|qaralgan sana=16-mart 2022-yil|til=inglizcha|arxivsana=28-fevral 2022-yil|arxivurl=https://web.archive.org/web/20220228180730/https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8}}</ref>.

== Faoliyat ==
2021-yil holatiga koʻra Sanofi kompaniyasining asosiy boʻlinmalari:

* Farmaseftika - dori vositalari ishlab chiqarish; 26,97 milliard yevro daromad;
* Vaksinalar (Sanofi Pasteur) — [[vaksinalar]] ishlab chiqarish; 6,32 milliard yevro daromad;
* Isteʼmolchi salomatligi - retseptsiz dori-darmonlarni ishlab chiqarish (hazm qilishni yaxshilash uchun analjeziklar, antiallergik preparatlar); daromadi 4,47 milliard yevro.

Mustaqil Davlatlar Hamdoʻstligi davlatlarida eng mashhur Sanofi dori-darmonlari Essentiale, Amaryl (Glimepiride), Arava (Leflunomid), Granocyte (Lenograstim), Dalfaz (Alfuzonin), Clexane (Enoxaparin), Cordarone (Amiodarone), Lokren (Betaxolol), No- shpa (Drotaverin), Plavix (Clopidogrel), Rovamitsin ([[Spiramitsin|Spiramisin]]), Solian (Amisulprid), Sofradex (framitsetin sulfat, gramitsidin, deksametazon), Tavanik ([[Levofloksatsin]]), Taxotere (Docetaxel), Telfastlin (Fexotalin), Festal (pankreatin), eloksatin (oksaliplatin), bronxikum (sabzavot tarkibi), depakin (valpik kislota), insuman (inson insulinlari), kogitum (atsetilaminosuksinik kislota), apidra ([[Insulin|insulin glulisin)]] [[Adrenalin|,]] ultrakain (artikain malaksi) + Magniy) gidroksid), Lantus (insulin glargin), Aprovel (Irbesartan) / CoAprovel (Irbesartan + gidroxlorotiyazid), OptiPen® Pro1 shprits qalam, Magne B6 (magniy-piridoksin), Lazolvan (Ambroksol), Lazolvan [[Togʻjambil|kekik]] ekstrakti) hisoblanadi.

* Aventis fondi<ref>{{Veb manbasi|url=http://www.aventis-foundation.org/|sarlavha=Aventis Foundation|qaralgan sana=8-oktabr 2011-yil|arxivsana=14-aprel 2021-yil|arxivurl=https://web.archive.org/web/20210414193857/http://www.aventis-foundation.org/}}</ref> - sanʼat, ijtimoiy hayot, fan sohasidagi xayriya faoliyati;
* Fondation Sanofi-Espoir<ref>{{Veb manbasi|url=http://www.fondation-sanofi-espoir.com/en/|sarlavha=Fondation Sanofi-Espoir|qaralgan sana=8-oktabr 2011-yil|arxivsana=17-may 2015-yil|arxivurl=https://web.archive.org/web/20150517022846/http://fondation-sanofi-espoir.com/en/}}</ref> - rivojlanayotgan mamlakatlarda sogʻliqni saqlashga xayrixohlik;
* Bemorlarga yordam berish fondi<ref>{{Veb manbasi|url=https://patientassistanceprogram.sanofi-aventis.us/|sarlavha=Patient Assistance|qaralgan sana=8-oktabr 2011-yil|arxivsana=11-dekabr 2011-yil|arxivurl=https://web.archive.org/web/20111211055241/http://patientassistanceprogram.sanofi-aventis.us/}}</ref> - bu dori sotib olishga moliyaviy imkoniyati boʻlmagan AQSh aholisi uchun xayriya dasturi.

=== Faoliyat geografiyasi ===
Asosiy ishlab chiqarish quvvatlari Fransiya, Germaniya, AQSH, Belgiya, Irlandiya, Vengriya, Turkiya, Braziliya, Italiya, Meksika, Hindiston va Kanadada joylashgan. Kompaniyaning AQShda 8 ta, Fransiyada 5 ta, Xitoyda 3 ta, Germaniya, Belgiya, [[Niderlandiya]] va Kanadada bittadan tadqiqot laboratoriyalari mavjud<ref name="ar2021">{{Veb manbasi|sarlavha=Annual Report 2021|url=https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8|sana=2022-02-23|nashriyot=Sanofi Group|qaralgan sana=16-mart 2022-yil|til=inglizcha|arxivsana=28-fevral 2022-yil|arxivurl=https://web.archive.org/web/20220228180730/https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8}}</ref>.

2021-yilda aylanmasi boʻyicha faoliyatning asosiy hududlari<ref name="ar2021">{{Veb manbasi|sarlavha=Annual Report 2021|url=https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8|sana=2022-02-23|nashriyot=Sanofi Group|qaralgan sana=16-mart 2022-yil|til=inglizcha|arxivsana=28-fevral 2022-yil|arxivurl=https://web.archive.org/web/20220228180730/https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8}}</ref>:

* Shimoliy Amerika - 15,1 milliard yevro;
** AQSh — 14,4 milliard yevro;
* [[Yevropa]] - 9,8 milliard yevro;
** Fransiya - 2,26 milliard yevro;
* Boshqa davlatlar - 12,9 milliard yevro;
** Xitoy - 2,72 milliard yevro;
** Yaponiya - 1,66 milliard yevro;
** Braziliya - 0,82 milliard yevro;
** Rossiya - 0,58 milliard yevro.

{| class="wikitable"
|+Moliyaviy koʻrsatkichlar milliard [[Yevro|(yevroda)]]<ref>{{Veb manbasi|sarlavha=Annual Report 2005 on SEC Filing Form 20-F|url=https://www.sec.gov/Archives/edgar/data/1121404/000119312506069546/d20f.htm|sana=2006-03-31|nashriyot=Sanofi|kirish sanasi=22-fevral 2017-yil|til=inglizcha|arxivsana=20-may 2016-yil|arxivurl=https://web.archive.org/web/20160520040042/http://www.sec.gov/Archives/edgar/data/1121404/000119312506069546/d20f.htm}}</ref><ref>{{Veb manbasi|sarlavha=Annual Report 2010 on SEC Filing Form 20-F|url=https://www.sec.gov/Archives/edgar/data/1121404/000119312511050947/d20f.htm|sana=2011-03-01|nashriyot=Sanofi|kirish sanasi=22-fevral 2017-yil|til=inglizcha|arxivsana=4-fevral 2021-yil|arxivurl=https://web.archive.org/web/20210204022853/https://www.sec.gov/Archives/edgar/data/1121404/000119312511050947/d20f.htm}}</ref><ref>{{Veb manbasi|sarlavha=Annual Report 2015 on SEC Filing Form 20-F|url=https://www.sec.gov/Archives/edgar/data/1121404/000119312516493072/d246196d20f.htm|sana=2016-03-04|nashriyot=Sanofi|kirish sanasi=22-fevral 2017-yil|til=inglizcha|arxivsana=23-fevral 2017-yil|arxivurl=https://web.archive.org/web/20170223043357/https://www.sec.gov/Archives/edgar/data/1121404/000119312516493072/d246196d20f.htm}}</ref><ref name="ar2016">{{Veb manbasi|sarlavha=Annual Report 2016|url=http://en.sanofi.com/Images/49216_FY2016_documentation.zip|sana=2017-02-08|nashriyot=Sanofi Group|qaralgan sana=20-fevral 2017-yil|til=inglizcha|arxivurl=https://web.archive.org/web/20170220174532/http://en.sanofi.com/Images/49216_FY2016_documentation.zip|arxivsana=2017-02-20}}</ref><ref name="ar2021">{{Veb manbasi|sarlavha=Annual Report 2021|url=https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8|sana=2022-02-23|nashriyot=Sanofi Group|qaralgan sana=16-mart 2022-yil|til=inglizcha|arxivsana=28-fevral 2022-yil|arxivurl=https://web.archive.org/web/20220228180730/https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8}}</ref>
!
!2004-yil
! 2005-yil
! 2006-yil
! 2007-yil
! 2008-yil
! 2009-yil
! 2010-yil
! 2011-yil
! 2012-yil
! 2013-yil
! 2014-yil
! 2015-yil
! 2016-yil
! 2017-yil
! 2018-yil
! 2019-yil
! 2020-yil
! 2021-yil
|-
| Aylanmasi
| 14.87
| 27.31
| 28.37
| 28.05
| 27.57
| 29.31
| 30.38
| 33.39
| 34.95
| 30.97
| 31.69
| 34.54
| 33.82
| 35.07
| 35.68
| 37.63
| 37.37
| 39.18
|-
| Sof foyda
| -3,665
| 2.202
| 4.006
| 5.263
| 3.851
| 5.265
| 5.467
| 5.646
| 4888
| 3.716
| 4390
| 4.287
| 4800
| 8.416
| 4.306
| 2.754
| 12.29
| 6.223
|-
| Aktivlar
| 82,85
| 86.24
| 77,76
| 71,91
| 71,99
| 80.25
| 85.26
| 100.7
| 100.4
| 96.06
| 97.39
| 102.3
| 104.7
| 99,81
| 111.4
| 112.6
| 114.4
| 120.2
|-
| Kapital
| 41.63
| 46.40
| 45.60
| 44.54
| 44.87
| 48.32
| 53.10
| 56.19
| 57.35
| 56.9
| 56.12
| 58.05
| 57,72
| 58.07
| 58.88
| 59.06
| 63.25
| 69.03
|}
<small>Eslatma. 2004—2011 yillarda - Sanofi-Aventis.</small>

=== Dori-darmonlar ===
2021-yilda quyidagi dorilar eng koʻp sotilgan:

* Dupixent (dupilumab, Dupixent) — atopik dermatit, [[bronxial astma]], 5,25 milliard yevro;
* Lantus (Lantus) — [[insulin]] analogi, 2,49 milliard yevro;
* Aubagio (teriflunomid, Aubagio) — koʻp skleroz, 1,96 milliard yevro;
* Lovenox (enoksaparin natriy, Lovenox) — [[Tromboz (tibbiyot)|tromboz]] va tromboemboliya, 1,49 milliard yevro;
* Myozyme - Pompe kasalligi, 1,00 milliard yevro;
* Tujeo (Toujeo) — [[insulin]] analogi, 0,97 milliard yevro;
* Plavix (klopidogrel, Plavix) — yurak xuruji va qon tomirlari, 0,93 milliard yevro.

=== Vaksinalar ===
Sanofi-Pasterning vaktsina boʻlimi Rossiya bozorida quyidagi infeksiyalarga qarshi vaksinalarni tarqatadi: [[vabo]], [[difteriya]], Haemophilus influenzae b tipidagi infeksiya (HIB infeksiyasi), [[meningokokk]] infeksiyalari, [[Koʻkyoʻtal|koʻk yoʻtal]], pnevmokokk infeksiyalari, [[qoqshol]], [[sil]], sil [[Ich terlama|kasalligi]] . [[gepatit A]], [[Gepatit B viruslari|gepatit B]], [[gripp]], yapon ensefaliti, [[qizamiq]], [[parotit]], [[Poliomiyelit|poliomielit]], [[quturish]], qizilcha, suvchechak, sariq isitma.

== Birlashgan kompaniyalar ==
2021-yil holatiga koʻra asosiy hamkor korxonalari<ref name="ar2021">{{Veb manbasi|sarlavha=Annual Report 2021|url=https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8|sana=2022-02-23|nashriyot=Sanofi Group|qaralgan sana=16-mart 2022-yil|til=inglizcha|arxivsana=28-fevral 2022-yil|arxivurl=https://web.archive.org/web/20220228180730/https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Form-20-F-2021.pdf?la=en&hash=CAAE985DF6C8BE3934517A429AD5ECA8}}</ref>:

* Aventis Inc. (AQSH)

Genzyme korporatsiyasi (AQSh) Genzyme Europe BV (Niderlandiya) Hoechst GmbH (Germaniya) Sanofi-Aventis Deutschland GmbH (Germaniya) Sanofi-Aventis Participations SAS (Fransiya) Sanofi-Aventis Singapore Pte Ltd (Singapur) Sanofi Foreign Biotechnology (Fr Partiance BV) (Niderlandiya) Sanofi Winthrop Industrie (Fransiya) Sanofi Pasteur Inc. (AQSH)

== Manbalar ==
<references group="" responsive="1"></references>

== Havolalar ==

* [https://web.archive.org/web/20110507132105/http://en.sanofi-aventis.com/ Kompaniyaning rasmiy sayti]
* [http://www.sanofi-aventis.ru Rossiyadagi kompaniya veb-sayti]
* [http://www.moitabletki.ru/info/sanofi-fires-viehbacher.html Sanofi Vibacherni ishdan bo'shatdi]
* [https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&type=20-F&dateb=&owner=exclude&count=40 Sanofi] Qimmatli qogʻozlar va birja komissiyasi veb-saytida{{Ref-en}} <small class="ref-info" style="cursor:help;" title="на английском языке">)</small>
[[Turkum:Farmaseftika]]
[[Turkum:Fransiya]]
[[Turkum:Dorixonalar]]
[[Turkum:Dorivor oʻsimliklar]]